606 related articles for article (PubMed ID: 33918704)
1. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E; Mercier MC; Etienne-Selloum N; Dontenwill M; Choulier L
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918704
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
3. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
Farrell C; Shi W; Bodman A; Olson JJ
J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
Lau D; Magill ST; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for the treatment of glioblastoma.
Gil-Gil MJ; Mesia C; Rey M; Bruna J
Clin Med Insights Oncol; 2013; 7():123-35. PubMed ID: 23843722
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies of recurrent glioblastoma and its molecular pathways 'Lock up the beast'.
El-Khayat SM; Arafat WO
Ecancermedicalscience; 2021; 15():1176. PubMed ID: 33680090
[TBL] [Abstract][Full Text] [Related]
10. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
Lu-Emerson C; Duda DG; Emblem KE; Taylor JW; Gerstner ER; Loeffler JS; Batchelor TT; Jain RK
J Clin Oncol; 2015 Apr; 33(10):1197-213. PubMed ID: 25713439
[TBL] [Abstract][Full Text] [Related]
11. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.
Redjal N; Nahed BV; Dietrich J; Kalkanis SN; Olson JJ
J Neurooncol; 2020 Nov; 150(2):165-213. PubMed ID: 33215343
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
13. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
14. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma.
Winograd E; Germano I; Wen P; Olson JJ; Ormond DR
J Neurooncol; 2022 Jun; 158(2):265-321. PubMed ID: 34694567
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
Niyazi M; Harter PN; Hattingen E; Rottler M; von Baumgarten L; Proescholdt M; Belka C; Lauber K; Mittelbronn M
Oncotarget; 2016 Jan; 7(3):2313-28. PubMed ID: 26575171
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways.
Arbab AS; Ali MM
Nov Approaches Cancer Study; 2020; 4(5):398-401. PubMed ID: 32924014
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]